Figure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Soyoung Lee; Kyunghwan Kim; Hye‐Jin Jeong; Subin Choi; Himchan Cheng; Dayoung Kim; Soomin Heo; Jinhee Mun; Minjong Kim; Eunjin Lee; Yoon Ji Choi; Seon‐gyeong Lee; Eun A Lee; Yewon Jang; Kayeong Lim; Heon Seok Kim; Euihwan Jeong; Seung‐Jae Myung; Deok‐Beom Jung; Chang Sik Yu; In Ho Song; M. Ryan Corces; Joo H. Kang; Kyungjae Myung; Taejoon Kwon; Tae‐Eun Park; Jinmyoung Joo; Seung Woo Cho

doi:10.1158/0008-5472.29760155

Key Points

MAIN FINDING: Multiplexed CRISPR/Cas9 effectively targets and treats cancer cells in xenograft tumors.
KEY EVIDENCE: High-resolution images reveal significant differences in tumor response between treated and untreated groups.
APPROACH: The method utilized LNPs to deliver CRISPR/Cas9 components directly to the tumors in HCT-116 models.
SIGNIFICANCE: This advancement in precision medicine may improve therapeutic strategies for cancer treatment.

Implication

Immunohistochemical analysis shows that multiplexed CRISPR/Cas9 efficiently targets tumors, suggesting its potential in cancer treatment.

Abstract

Figure S9 provides high-resolution whole-slide immunohistochemical images of HCT-116 xenograft tumors treated with either PBS or multiplexed CRISPR/Cas9WT RNP-loaded LNPs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0272 https://doi.org/10.1158/0008-5472.29760155

View Full Paper

Ask AI

Bookmark

Share

Figure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading